Pharmaco - Articles

Andrew Curl from the ABPI explains more about the industry's ability to innovate and provide world-beating medicines.
A Moderator said: Spencer wants to know: "Is money allocated for research solely on how many people the particular disease kills or is it more to do with how much money the drug can be sold for?" Andrew Curl said: Money is allocated to research based on whether there is a un met medical need. If there is then this is an attractive area for medical research. A Moderator said: Adam wants to know: "Why is only 12% of the NHS budget spent on medicine when it is so vital to a patients care?" Andrew Curl said: It is up to the NHS how it spends its money but the amount spent in the UK is only approximately a half what is spent in Europe on medicines per hea…

This edition of "Emerging Drug Discovery Targets" features a potential approach to the treatment of COPD; Ligands' retinoic acid receptor agonist with appetite suppressive and insulin sensitizing properties; the use of HDAC inhibitors for the treatment of rheumatoid arthritis; Tamoxifen as a dual chemopreventative and anti-atherosclerosis treatment; and broad based inhibition of multidrug resistance proteins for improved cancer treatment. As usual we also provide updates on industrial advances a
  Emerging Drug Discovery Targets from LeadDiscovery 6th February 2004 to view this alert on line please go to http://www.leaddiscovery.co.uk/TherapeuticAdvances%20Archive/Feb%206th%20emerging%20targets.htm ************************************** "Emerging Drug Discovery Targets" provides a twic…

Pharma NewsBytes selects out what we consider as being some of the most interesting press releases to have appeared on our DailyUpdates tracking service over the past few weeks. Currently featured new items focus on a number of novel approaches to the treatment of cancer including the development of caspase inhibitors; gene therapy approaches to the expression of TNF-alpha; an advanced monoclonal antibody; and a strategy to block XIAP. In addition new therapeutics for the treatment of rheumatoid
Pharma NewsBytes features selected press releases recently featured on DailyUpdates and offers the reader a leisurely stroll through the past few weeks of activity from within the pharmaceutical industry. Selected press releases - January 19th-February 2nd Advances in novel approaches towards the…

According to WHO, there are some 130 million diagnosed diabetics in the world. The market for diabetes therapeutics is rising. Oral antidiabetic drugs, the leading class of drugs used to treat the disease, accounted for almost 63% of sales during this period, while sales of insulin stand at around 30%. Further increases are inevitable and the market for diabetes medications could exceed $20 billion by 2006. The largest unmet need in the diabetes market is improved delivery of insulin. Currently,
According to WHO, there are some 130 million diagnosed diabetics in the worlds, a figure that is predicted to increase to 300 million by 2025.  The majority of patients suffer from type 2 diabetes however type 1 diabetes (also known as insulin-dependent diabetes (IDDM) or juvenile-onset diabete…

Pharmaceutical Education Associates’ presents a one-of-a-kind forum exploring the most recent and clinically relevant research pertaining to brain targets for the enhancement of cognitive function. Of particular interest will be the effectiveness of new cognition-enhancing drugs in the treatment of neurodegenerative disorders such as Alzheimer’s disease, as well as their potential for the treatment of the cognitive decline associated with normal aging or as a prelude to disease.
Emerging Molecular Targets to Treat Disorders Affecting Cognitive Function The Westin Princeton at About this Conference Pharmaceutical Education Associates’ presents a one-of-a-kind forum exploring the most recent and clinically relevant research pertaining to brain targets for the enhancement of cognitive fun…

a Bristol based Biochemical Company, says it has invented a new sprayable antibacterial disinfectant agent, to be launched under the name of D-Stroy, that can kill the hospital superbug MRSA and TB.
Greenbridge, a based Biochemical Company, says it has invented a new sprayable antibacterial disinfectant agent, to be launched under the name of D-Stroy, that can kill the hospital superbug MRSA and TB. Greenbridge claims their product will revolutionise hospital hygiene. The news comes after a study commissioned by the company revealed that the is at risk of a severe epidemic of MRSA, or methicillin-resistant staphylococcus aureas. Lethal traces of the superbug were found in many public places, the authors of the study claimed. It is feared that the bug could kill up to 150,000 hospital pat…

This edition of features new generation oncolytic viruses from Cell Genesys active against colorectal cancer cells; a p38 MAPK inhibitor for the treatment of rheumatoid arthritis from Fujisawa; data describing the anti-angiogenic activity of bisphosphonates in cancer models; a new JAK3 inhibitor from Pfizer for transplant rejection; and an integrin antagonist from Merck for the treatment of osteoporosis. As usual updates on industrial advances and licensing opportunities are provided.
  Emerging Drug Discovery Targets from LeadDiscovery 18th December 2003 to view this alert on line please go to http://www.leaddiscovery.co.uk/TherapeuticAdvances%20Archive/Dec%2018th%20emerging%20targets.htm ************************************** "Emerging Drug Discovery Targets" provides a twice monthl…

Transplantation immunotherapy commonly involves the use of azathioprine often combined with low doses of cyclosporine. Increased susceptibility to infection and severe toxicity represent serious adverse effects and a newer molecular target being investigated for the prevention of transplant rejection is Janus tyrosine kinase 3 (Jak3). Jak3 is this months "Target of the Month" from LeadDiscovery's and here they describe Pfizer's efforts to optimize inhibitors of this kinase
The global market for immunosuppressant therapy is in excess of 4 billion USD per year. This therapeutic class is used for the treatment of both autoimmune diseases (see our recent analysis of rheumatoid arthritis therapeutics) and for the prevention of organ rejection in transplantation. Since the first successful kidn…

Pharma NewsBytes selects out what LeadDiscovery considers as being some of the most interesting press releases to have appeared on their DailyUpdates tracking service over the past few weeks. Currently featured new items focus on development activity in the field of Alzheimer's disease; advances in autoimmune diseases and inflammatory disorders; and news from the 26th Annual San Antonio Breast Cancer Symposium
LeadDiscovery's intelligence service, DailyUpdates has evolved as a key tool to help all in the drug development sector keep track of breaking journal articles, press releases and pharmaceutical reports. Pharma NewsBytes features selected press releases recently featured on DailyUpdates and offers the reader a leisurely stroll through the past few weeks of activity from within the ph…

This comprehensive one-day training offers MSLs, their managers and those interested in a better understanding of the profession an overview of what the job entails, best practices and realistic ways to incorporate them into your own job. The training will focus on the components of a successful career as a MSL, as opposed to educating on individual therapeutic types.
Field-based medical science liaisons (MSLs) play a vital role within pharmaceutical and biotechnology organizations. The variety of responsibilities they have directly affects the success of a therapeutic agent, as MSLs engage Key Opinion Leaders (KOLs) for their products, help develop company marketing and educational programs, and communicate vital information to sales teams, health practitioners and clinical investigators.&…

This edition of "Emerging Drug Discovery Targets" features a potent histone deacetylase inhibitor from Norvartis for the treatment of cancer, two new approaches to metabolic disorders and VEGFR-1 as a target for rheumatoid arthritis. As usual we also provide updates on industrial advances and licensing opportunities.
  Emerging Drug Discovery Targets from LeadDiscovery 21st November 2003 to view this alert on line please go to http://www.leaddiscovery.co.uk/TherapeuticAdvances%20Archive/Nov%2021st%20emerging%20targets.htm ************************************** "Emerging Drug Discovery Targets" provides a twice monthly summary of some of the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. Information includes editorials on recently pub…

The field of histone deacetylation continues to receive considerable interest principally due to the ability of histone deacetylase (HDAC) inhibitors to produce cytostatic activity in cancer, but more recently due to the role that this class has in other indications such as autoimmune disorders. Novartis researchers have now developed a HDAC inhibitor of greater anti-proliferative potency than that of SAHA, and which almost completely blocked the growth of human colon and lung cancer xenografts
The field of histone deacetylation continues to receive considerable interest due to the ability of histone deacetylase (HDAC) inhibitors to modulate transcriptional activity. Molecules from this therapeutic class have the potential to occupy an indomitable position in the fast-moving cytostatic mark…

Pharma NewsBytes selects out what we consider as being some of the most interesting press releases to have appeared on our DailyUpdates tracking service over the past few weeks. Currently featured new items focus on development activity in the field of rheumatoid arthritis; advances in anti-hyperlipemia therapeutics; and the termination of MK-0869 development for the treatment of depression
LeadDiscovery's intelligence service, DailyUpdates has evolved as a key tool to help all in the drug development sector keep track of breaking journal articles, press releases and pharmaceutical reports. Pharma NewsBytes features selected press releases recently featured on DailyUpdates and offers the reader a leisurely stroll through the past few weeks of activity from within the pharmaceutical industry…

Personality tests are commonly at interviews to calculate your personality "Type". It is likely that you will be faced with one during your career.
Understanding about personality tests can be a big help should you have to face one and the best way to understand them is to do one. (You try one here for free. www.peoplemaps.co.uk/pharmiweb.htm) Your personality test results will reveal a range of things about you to a potential employer. Typically it will reveal your strengths, weaknesses and your preferred style of working and communicating. To begin with you will usually be asked to complete a Forced Choice Questionnaire if it is a sophisticated system. This can be an awkward thing at first as often you want to select two answers equally but the system will not let you do so. Get familia…

It is predicted that the annual value of the market for drugs used to treat autoimmune disease will exceed $20 billion in the next few years. Rheumatoid arthritis is one of the more common and difficult to treat autoimmune diseases and there is a great deal of interest in the discovery of novel drugs to treat this condition. This comprehensive report evaluates breaking drug discovery targets and therapeutic candidates for the treatment of this disease
The autoimmune diseases are receiving increasing attention in the pharmaceutical industry as progress is made in the understanding of immune and inflammatory processes. It is predicted that the annual value of the market for drugs used to treat autoimmune disease will exceed $20 billion in the next few years. Rheumatoid arthritis is one of th…

Emerging Drug Discovery Targets" provides a twice monthly summary of some of the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. This edition of features data highlighting technology for improved wound healing; a new candidate asthma treatment; a novel approach to diabetes and combination therapy offering improved radiotherapy responsiveness. As usual we also provide updates on industrial advances and licensing opportunities.
"Emerging Drug Discovery Targets" provides a twice monthly summary of some of the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. Information includes editorials on recently published journal articles, selected press releases and "intelligence reports". Our target au…

Pharma NewsBytes is LeadDiscovery’s selection of recent press releases for the drug development. Currently featured news items include those announcing promising clinical data for Antigenics' pancreatic cancer Oncophage vaccine; FDA backing for Forest's new Alzheimer's disease drug, Memantine; early figures on the sale of AstraZeneca's anti-cholerstremic drug Crestor; and FDA approval of Pfizer's potential blockbuster, Inspira for the treatment of congestive heart failure
LeadDiscovery's intelligence service, DailyUpdates has evolved as a key tool to help all in the drug development sector keep track of breaking journal articles, press releases and pharmaceutical reports. Pharma NewsBytes features selected press releases recently featured on DailyUpdates and offers the reader a leisurely st…

Worldwide, 95 million people suffer from wounds that result in tissue loss. Wound healing problems extend hospital stays, especially in the elderly, resulting in an additional $1.5 billion in healthcare costs in the US alone. LeadDiscovery’s current target of the month focuses on connexin43, blocking of which produces a dramatic improvement in wound healing. In this feature we also describe how antisense technology has been applied to develop a licensing opportunity in this area
Worldwide, an estimated 95 million people suffer from wounds that result in tissue loss. While acute wounds heal uneventfully, chronic wounds such as ulcers do not and often persist for months or years. In the case of the elderly, average hospital stays are increased by at least one week, resulting in an additional…

"Emerging Drug Discovery Targets" summarizes the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. This edition explores recent advances in the use of siRNA technology in oncology, new molecular targets for the treatment of diabetes and advances in the development of GSK-3 inhibitors. Recent preselected press releases are also highlighted and as usual new licensing opportunities, breaking publications and new industry reports are all identified.
"Emerging Drug Discovery Targets" provides a twice monthly summary of some of the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. Information includes editorials on recently published journal articles, selected press releases and "intelligence repor…

Proof of concept studies have accumulated supporting the targeting of glycogen synthase kinase-3 (GSK-3) for the treatment of diabetes and CNS conditions. Now inhibitors are emerging as therapeutic candidates
Since the mid-1990s there has been a near exponential rise in the level of glycogen synthase kinase-3 (GSK-3) related research. Consequently the therapeutic potential of GSK-3 inhibitors has become a major area of pharmaceutical interest. To mark this surge in interest, LeadDiscovery have recently produced a full report "Glycogen synthase kinase 3 (GSK-3) inhibitors:Proof of concept and therapeutic opportunities for the treatment of diabetes, Alzheimer's disease, stroke & bipolar disorders" (click here for access). The inhibition of GSK-3 offers considerable potential for the treat…